New shot aims to silence hepatitis b virus

NCT ID NCT06993480

Ongoing Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests an injection called AHB-137 in 20 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug can lower or eliminate hepatitis B surface antigen (HBsAg) and viral DNA, potentially leading to a functional cure. Participants receive weekly injections for 24 weeks, and researchers monitor immune responses and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-137 injection
What this could lead to: If successful, this could point toward a functional cure for chronic hepatitis B, where the virus is suppressed without lifelong medication.
What could go wrong: This is a small, early-phase trial with only 20 participants. It may not show strong enough antiviral effects, and risks include injection site reactions or immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.